{"id":"sglt2-inhibitor-glp-1-ra","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Polyuria"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":{"chemblId":"CHEMBL1240772","moleculeType":"Protein","molecularWeight":"3169.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal tubule, promoting urinary glucose excretion independent of insulin. GLP-1 receptor agonists activate GLP-1 receptors on pancreatic beta cells and in the brain, stimulating glucose-dependent insulin secretion and reducing appetite. The combination provides complementary glucose-lowering and weight-loss effects with potential cardiovascular and renal benefits.","oneSentence":"This dual-action drug combines SGLT2 inhibition (reducing glucose reabsorption in the kidney) with GLP-1 receptor agonism (enhancing insulin secretion and satiety) to lower blood glucose and body weight.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:07:44.491Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Cardiovascular risk reduction in type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05390892","phase":"PHASE4","title":"PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-09-26","conditions":"Type2Diabetes, ASCVD","enrollment":6000},{"nctId":"NCT06593314","phase":"NA","title":"Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-08-06","conditions":"Heart Failure, Diabetes","enrollment":800},{"nctId":"NCT05040087","phase":"NA","title":"Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2021-09-01","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT06046560","phase":"PHASE4","title":"Diabetes Remote Intervention to improVe Use of Evidence-based Medications","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-22","conditions":"Cardiovascular Diseases, Diabetes","enrollment":200},{"nctId":"NCT05526157","phase":"","title":"An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-10-01","conditions":"Chronic Kidney Disease, Type 2 Diabetes Mellitus","enrollment":50000},{"nctId":"NCT06475586","phase":"PHASE4","title":"Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Banja Luka","startDate":"2023-05-03","conditions":"Psoriasis Vulgaris, Diabetes Type 2","enrollment":30},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":239,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SGLT2 inhibitor, GLP-1 RA","genericName":"SGLT2 inhibitor, GLP-1 RA","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This dual-action drug combines SGLT2 inhibition (reducing glucose reabsorption in the kidney) with GLP-1 receptor agonism (enhancing insulin secretion and satiety) to lower blood glucose and body weight. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}